Monthly psychiatry bulletin — November 17, 2026
This issue covers October 18 to November 17, 2026, starting the day after the previous issue dated October 17. It includes eight items. Psychedelics dominated the month: a JAMA trial of intranasal mebufotenin, two single-dose phase 3 readouts, and Compass's completed FDA application for psilocybin. In schizophrenia and bipolar disorder, the FDA approved at-home use of sublingual dexmedetomidine and, according to Chinese press, China added xanomeline-trospium to its national reimbursement list. Several phase 3 readouts come from company press releases and have not yet been peer reviewed; this is flagged in each case.
Depression and anxiety
1. Intranasal mebufotenin for treatment-resistant depression: phase 2b randomized trial in JAMA
[Clinical trial] [Multinational: United States, Europe and Australia]
Phase 2b double-blind trial at 38 sites (JAMA, published online October 26; funded by Beckley Psytech, an AtaiBeckley company) in 193 adults with treatment-resistant depression (two to five prior failed treatments), randomized to a single intranasal dose of mebufotenin benzoate (5-MeO-DMT) 8 mg (n=46) or 12 mg (n=73), or 0.3 mg as comparator (n=74), with psychological support. On the MADRS at day 29, the difference versus comparator was −5.3 points with 12 mg (95% CI, −8.9 to −1.8; P=.003) and −6.2 with 8 mg (95% CI, −10.2 to −2.1; P=.003). Day 29 response was 34.8% with 8 mg, 34.2% with 12 mg and 12.2% with 0.3 mg. Discharge-readiness at two hours was met by 85% (8 mg) and 78% (12 mg); one participant on 12 mg had two severe treatment-related panic attacks.
Why it matters: a short-acting psychedelic that could allow sessions lasting only a few hours, which would change logistics compared with psilocybin; but the effect is moderate (about five to six points), follow-up is short (eight weeks), blinding is difficult with psychedelics, and the trial was company-funded. It does not change practice; in the Dominican Republic it is unavailable outside trials.
Sources
- [Article] Feifel D, Seynaeve M, Cubała WJ, et al. "Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial." JAMA. 2026. DOI: 10.1001/jama.2026.18380. https://jamanetwork.com/journals/jama/fullarticle/2855796
- [Coverage] HMP Global Learning Network (Psych Congress Network), November 2, 2026. https://www.hmpgloballearningnetwork.com/site/pcn/news/mebufotenin-shows-rapid-antidepressant-effects-phase-2b-trial
2. Single-dose DT120: two positive phase 3 trials in major depression and generalized anxiety
[Congress] [United States]
Presented as posters at the Neuroscience Education Institute (NEI) Fall Congress (Colorado Springs, November 5–8); the developer is Definium Therapeutics (formerly MindMed). In Emerge, 149 adults with major depressive disorder (83% severe) received a single 100 µg dose of DT120 (lysergide) orally disintegrating tablet or placebo: the placebo-adjusted MADRS difference was −8.1 points at week 6 and −7.3 at week 12 (P<.0001). In Voyage, 214 adults with generalized anxiety disorder: −5.4 points on the HAM-A at week 12, with response of 43% vs 16% and remission of 14% vs 4%. In Emerge, illusions (64%), euphoric mood (29%) and nausea (27%) predominated on dosing day; there were no serious adverse events.
Why it matters: the depression effect size is meaningful for a single dose, but these are manufacturer topline results, already announced by the company before this period and without peer-reviewed publication, and blinding is nearly impossible when almost two-thirds experience perceptual illusions; 52-week durability remains to be seen.
Sources
- [Coverage] HMP Global Learning Network (Psych Congress Network), November 12, 2026. https://www.hmpgloballearningnetwork.com/site/pcn/news/phase-3-dt120-trial-reports-early-and-sustained-mdd-improvement
3. HLP003, deuterated psilocin as adjunctive treatment in major depression: phase 3 topline results
[Industry] [North America]
On November 16, Helus Pharma reported topline results of APPROACH: 222 adults (intent-to-treat population) with moderate-to-severe major depressive disorder on a stable antidepressant, 112 on HLP003 and 110 on placebo. MADRS fell by 19.5 versus 11.9 points at week 6 (difference 7.6; P<.0001), with separation from day 2 (5.0 points) maintained at week 12 (7.0). Response: 56.3% vs 28.2%; remission: 50.9% vs 18.2%. There were three treatment-related serious adverse events.
Why it matters: phase 3 data for a psychedelic as augmentation of an antidepressant, a common clinical scenario; but these are press-release topline results without details on serious adverse events or durability, and they still need the second pivotal trial (EMBRACE) and peer-reviewed publication.
Sources
- [Coverage] Psychiatric Times, November 16, 2026. https://www.psychiatrictimes.com/view/morning-rounds-news-from-november-9-16
- [Coverage] PharmaShots, November 17, 2026. https://pharmashots.com/37666/helus-hlp003-approach-mdd
- [Official release] Helus Pharma, July 21, 2026. https://www.biospace.com/press-releases/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-in-adjunctive-treatment-of-major-depressive-disorder-ahead-of-schedule
4. Compass completes its FDA application for COMP360 psilocybin
[Regulatory FDA] [United Kingdom / United States]
On November 9, Compass Pathways announced it completed its New Drug Application (NDA) for COMP360, a synthetic psilocybin, for treatment-resistant depression, based on two phase 3 trials and one phase 2b study (more than 1,000 participants in total, per the company). It expects launch in the first half of 2027 if approved, but psilocybin is a Schedule I substance and would need DEA rescheduling. On November 12, according to sources cited by Reuters, the FDA has reportedly shelved the Commissioner's National Priority Voucher program, which included COMP360; the Department of Health and Human Services (HHS) disagrees and says the pilot is ongoing.
Why it matters: a formal approval application for a psychedelic in depression, but an application is not an approval, and uncertainty about the priority voucher could lengthen timelines. No immediate impact on Latin American practice.
Sources
- [Official release] Compass Pathways, November 9, 2026. https://via.ritzau.dk/pressemeddelelse/15277398/compass-pathways-completes-comp360-psilocybin-new-drug-application-to-us-fda-for-treatment-resistant-depression?publisherId=90456
- [Coverage] Psychiatric Times, November 9, 2026. https://www.psychiatrictimes.com/view/nda-submission-complete-comp360-psilocybin-for-treatment-resistant-depression
- [Coverage] Reuters, November 12, 2026. https://www.reuters.com/world/us-fda-shelves-commissioners-voucher-program-speedy-drug-reviews-sources-say-2026-11-12/
- [Coverage] Psychiatric Times, November 12, 2026. https://www.psychiatrictimes.com/view/fda-shelves-fast-track-drug-review-initiative
- [Coverage] Psychiatric Times, November 16, 2026. https://www.psychiatrictimes.com/view/morning-rounds-news-from-november-9-16
Schizophrenia and bipolar disorder
5. China adds xanomeline-trospium to its national reimbursement list, per Chinese press
[Public health / access] [China]
On November 14, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the 2026 national basic medical insurance drug catalogue, with 107 new drugs (51 Class 1 innovative drugs), effective January 1, 2027. According to Chinese press, it includes xanomeline-trospium capsules (Zai Lab) for adult schizophrenia, the first antipsychotic without direct dopamine action (M1/M4 muscarinic agonist) to enter the list, about one year after its approval in China.
Why it matters: reimbursement, more than approval, determines real access to an expensive drug; it signals that the muscarinic mechanism is entering public systems outside the United States. (Sources in Chinese.)
Sources
- [Regulator] China National Healthcare Security Administration and Ministry of Human Resources and Social Security, notice issuing the national basic medical insurance drug catalogue (2026), November 14, 2026. http://www.nhsa.gov.cn/art/2026/11/14/art_104_23384.html
- [Coverage] Xin Kuai Bao (via Sina), November 14, 2026. https://k.sina.cn/article_1652484947_627eeb53020022i9m.html
- [Coverage] Guangming (gmw.cn), November 14, 2026. https://m.gmw.cn/2026-11/14/content_1304586055.htm
6. FDA approves at-home use of sublingual dexmedetomidine (Igalmi) for acute agitation
[Regulatory FDA] [United States]
On November 16, Teva announced that the FDA approved dexmedetomidine sublingual film (Igalmi) for the acute treatment of agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, including at home; until now it could only be given under the supervision of a healthcare provider. The approval is based on the phase 3 SERENITY At-Home trial (randomized, double-blind, placebo-controlled, 12 weeks), with 102 patients and 1,160 treated agitation episodes, whose primary endpoint was at-home safety and tolerability and which, per Teva, was met. The most common adverse events were somnolence, dry mouth, dizziness, and oral paresthesia or hypoesthesia; the label warns of hypotension, orthostatic hypotension and bradycardia.
Why it matters: it opens the possibility of treating agitation episodes without an emergency visit, but the pivotal trial measured safety and tolerability, not at-home efficacy, and the data come from the company; it requires selecting patients and caregivers able to recognize hypotension and sedation, and monitoring interactions with antihypertensives, cardiac drugs, sedatives and opioids.
Sources
- [Official release] Teva, November 16, 2026. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--FDA-Approves-IGALMI-as-First-At-Home-Acute-Treatment-for-Agitation-Associated-with-Schizophrenia-Schizoaffective-Disorder-or-Bipolar-I-or-II-Disorder-in-Adults/default.aspx
- [Coverage] HCPLive, November 16, 2026. https://www.hcplive.com/view/fda-approves-dexmedetomidine-home-schizophrenia-bipolar-agitation
- [Coverage] Psychiatric Times, November 16, 2026. https://www.psychiatrictimes.com/view/morning-rounds-news-from-november-9-16
Addictions
7. Integrated mobile units for people who inject drugs do not improve treatment uptake (HPTN 094)
[Clinical trial] [United States]
Open-label randomized trial (JAMA Psychiatry, November 4; funded by the NIH through NIDA) in five cities with 409 people with opioid use disorder who inject drugs, without HIV and not on medication for OUD. Both groups received 26 weeks of peer navigation; the intervention group (n=203) also received buprenorphine, HIV pre-exposure prophylaxis and clinical services on a mobile unit, and the control group (n=206) was referred to existing community services. At week 26, MOUD use was 14.8% vs 10.7% and PrEP use 5.4% vs 2.9%. No statistically significant differences were detected in the coprimary outcomes at 26 weeks. Mortality at 52 weeks was lower with the mobile unit (4 vs 13 deaths; HR 0.29; 95% CI, 0.1 to 0.9), a secondary outcome that, according to the NIH release, needs replication.
Why it matters: bringing services to the street is not enough to increase treatment uptake in this population; the mortality signal deserves replication. Applicable to Caribbean harm-reduction programs, with caution given the US fentanyl context.
Sources
- [Article] Shoptaw S, El-Bassel N, Hanscom B, et al. "Mobile Units for Integrated Addiction and HIV Prevention Services for People Who Inject Drugs: The HPTN 094 Randomized Clinical Trial." JAMA Psychiatry. 2026. DOI: 10.1001/jamapsychiatry.2026.3644. http://dx.doi.org/10.1001/jamapsychiatry.2026.3644
- [Official release] NIH (Office of the Director), November 4, 2026. https://www.eurekalert.org/news-releases/1150409
- [Registry] NCT04804072, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04804072
Child and adolescent psychiatry and public mental health
8. Ecological momentary assessment and digital safety planning in young people at risk of suicide
[Publication] [Spain]
Case series (Frontiers in Psychiatry, November 3) of four participants aged 14 to 22 from the SmartCrisis 2.0 and SmartCrisis-Teen randomized trials at two Madrid university hospitals. Apps were rated favorably (uMARS 3.42 to 4.84 out of 5), but EMA completion among those who used it ranged from 33.8% to 67.6%, only one participant actively used the safety plan, and in one case suicidal behavior occurred without a prior rise in self-reported ideation.
Why it matters: four selected cases cannot show effectiveness; the value is qualitative: app-based monitoring does not replace clinical assessment, because crises can emerge without warning in self-reports. Results of the parent randomized trials will be what counts.
Sources
- [Article] Loewen Á, Herrmann FM, Peñuelas-Calvo I, et al. "Young people at risk of suicide. ecological momentary assessment and digital safety planning in a case series." Front Psychiatry. 2026;17:1983683. DOI: 10.3389/fpsyt.2026.1983683. Open access (CC BY). https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1983683/full
If you or someone close to you is in crisis, contact emergency services (911 in the Dominican Republic) or a crisis helpline.
Upcoming meetings and dates
Next relevant meeting: the 65th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), January 10–13, 2027, in San Diego, United States.
https://acnp.org/
Ready-to-paste WhatsApp text
*Psychiatry Bulletin — November 2026* Greetings, colleagues. The most relevant news from October 18 to November 17: 🧠 *Depression and anxiety* *Intranasal mebufotenin in treatment-resistant depression (JAMA, phase 2b)* n=193, single dose: MADRS -5.3 to -6.2 vs comparator at day 29; response 35% (8 mg) and 34% (12 mg) vs 12%. https://jamanetwork.com/journals/jama/fullarticle/2855796 *Single-dose DT120: two positive phase 3 trials* Depression (n=149): MADRS -8.1 at 6 weeks. Generalized anxiety (n=214): HAM-A -5.4. Congress data. https://www.hmpgloballearningnetwork.com/site/pcn/news/phase-3-dt120-trial-reports-early-and-sustained-mdd-improvement *Adjunctive HLP003 in major depression (phase 3)* n=222: remission 50.9% vs 18.2% at 6 weeks. Press release, unpublished. https://www.psychiatrictimes.com/view/morning-rounds-news-from-november-9-16 *Compass files for FDA approval of its psilocybin* COMP360 for treatment-resistant depression; launch expected in 2027 if approved. https://via.ritzau.dk/pressemeddelelse/15277398/compass-pathways-completes-comp360-psilocybin-new-drug-application-to-us-fda-for-treatment-resistant-depression?publisherId=90456 💊 *Schizophrenia and bipolar disorder* *China will reimburse xanomeline-trospium from January 2027* First muscarinic antipsychotic on its national list (per Chinese press). https://k.sina.cn/article_1652484947_627eeb53020022i9m.html *FDA approves Igalmi (sublingual dexmedetomidine) for agitation at home* SERENITY At-Home: 102 patients and 1,160 episodes; primary endpoint of safety and tolerability. https://www.hcplive.com/view/fda-approves-dexmedetomidine-home-schizophrenia-bipolar-agitation 🚭 *Addictions* *Mobile units for people who inject drugs (HPTN 094)* n=409: no statistically significant increase in opioid treatment (14.8% vs 10.7%). http://dx.doi.org/10.1001/jamapsychiatry.2026.3644 👥 *Youth mental health* *Digital safety plan in young people at risk of suicide* Series of 4 cases in Madrid: little use of the plan; the app does not replace clinical assessment. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1983683/full If someone is in crisis, emergency services and crisis lines are available. Full bulletin and audio: https://boletinesmedicos.com/en/psychiatry/2026-11-17.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
Monthly psychiatry bulletin — November 2026 Eight verified items from October 18 to November 17, from JAMA, JAMA Psychiatry, Frontiers in Psychiatry, industry announcements and Chinese press. Three worth your time: • Intranasal mebufotenin for treatment-resistant depression (JAMA, phase 2b, n=193): a single dose lowered MADRS 5 to 6 points more than comparator at day 29. Limitation: moderate effect and eight-week follow-up. • HLP003, deuterated psilocin as adjunct (phase 3, n=222): remission 50.9% vs 18.2% at six weeks. Limitation: press release without peer review. • HPTN 094 (JAMA Psychiatry, n=409): integrated mobile units did not significantly increase opioid treatment over peer navigation (14.8% vs 10.7%). Limitation: the lower mortality seen is a secondary outcome. Full bulletin, with critical appraisal of each study and links to sources: https://boletinesmedicos.com/en/psychiatry/2026-11-17.html #Psychiatry #MentalHealth #Psychedelics #Depression #Addiction
Ready-to-paste X (Twitter) post
Intranasal mebufotenin in treatment-resistant depression: response 35% and 34% vs 12% (JAMA, phase 2b, n=193). Adjunctive psilocin phase 3: remission 50.9% vs 18.2% (press release). Psychiatry bulletin: https://boletinesmedicos.com/en/psychiatry/2026-11-17.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.